Head-To-Head Comparison: Astrana Health (NASDAQ:ASTH) & Fresenius SE & Co. (OTCMKTS:FSNUY)

Astrana Health (NASDAQ:ASTH) and Fresenius SE & Co. (OTCMKTS:FSNUY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Astrana Health and Fresenius SE & Co., as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrana Health	0	3	6	0	2.67
Fresenius SE & Co.	0	0	2	1	3.33

Astrana Health currently has a consensus target price of $53.2857, indicating a potential upside of 77.97%. Given Astrana Health’s higher probable upside, equities research analysts plainly believe Astrana Health is more favorable than Fresenius SE & Co..

Volatility & Risk

Astrana Health has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Fresenius SE & Co. has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Earnings & Valuation

This table compares Astrana Health and Fresenius SE & Co.”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrana Health	$2.42 billion	0.69	$43.15 million	$0.51	58.71
Fresenius SE & Co.	$23.63 billion	N/A	$509.67 million	$0.53	25.72

Fresenius SE & Co. has higher revenue and earnings than Astrana Health. Fresenius SE & Co. is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

52.8% of Astrana Health shares are owned by institutional investors. 20.0% of Astrana Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Astrana Health and Fresenius SE & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Astrana Health	1.04%	3.43%	1.87%
Fresenius SE & Co.	5.09%	9.33%	4.32%

Summary

Fresenius SE & Co. beats Astrana Health on 8 of the 14 factors compared between the two stocks.

About Astrana Health

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.

About Fresenius SE & Co.

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.